Puma Biotechnology, Inc. and Medison Pharma Ltd. entered into an exclusive agreement under which Medison will commercialize NERLYNX® (neratinib) in Israel. NERLYNX is not approved currently for commercialization outside of the United States. Medison will be responsible for seeking the requisite regulatory approval and, once approved, for commercializing NERLYNX in Israel. Puma will receive upfront and milestone payments throughout the term of this agreement, as well as significant double digit royalties on NERLYNX sales in Israel.